Pharmacokinetics of vitamin D toxicity\textsuperscript{1–4}

Glenville Jones

ABSTRACT

Although researchers first identified the fat-soluble vitamin cholecalciferol almost a century ago and studies have now largely elucidated the transcriptional mechanism of action of its hormonal form, 1α,25-dihydroxyvitamin D\textsubscript{3} \([1\alpha,25(\text{OH})\textsubscript{2}D\textsubscript{3}]\), we know surprisingly little about mechanisms of vitamin D toxicity. The lipophilic nature of vitamin D explains its adipose tissue distribution and its slow turnover in the body (half-life \(\approx\) 2 mo). Its main transported metabolite, 25-hydroxyvitamin D\textsubscript{3} \([25(\text{OH})D\textsubscript{3}]\), shows a half-life of \(\approx\) 15 d and circulates at a concentration of 25–200 nmol/L, whereas the hormone 1α,25(OH)\textsubscript{2}D\textsubscript{3} has a half-life of \(\approx\) 15 h. Animal experiments involving vitamin D\textsubscript{3} intoxication have established that 25(OH)D\textsubscript{3} can reach concentrations up to 2.5 μmol/L, at which it is accompanied by hypercalcemia and other pathological sequelae resulting from a high Ca/PO\textsubscript{4} product. The rise in 25(OH)D\textsubscript{3} is accompanied by elevations of its precursor, vitamin D\textsubscript{3}, as well as by rises in many of its dihydroxy metabolites \([24,25(\text{OH})\textsubscript{2}D\textsubscript{3}; 25,26(\text{OH})\textsubscript{2}D\textsubscript{3};\text{and} 25(\text{OH})\textsubscript{3}D\textsubscript{26,23-lactone}]\) but not 1α,25(OH)\textsubscript{2}D\textsubscript{3}. Early assumptions that 1α,25(OH)\textsubscript{2}D\textsubscript{3} might cause hypercalcemia in vitamin D toxicity have been replaced by the theories that 25(OH)D\textsubscript{3} at pharmacologic concentrations can overcome vitamin D receptor affinity disadvantages to directly stimulate transcription or that total vitamin D metabolite concentrations displace 1α,25(OH)\textsubscript{2}D\textsubscript{3} from vitamin D binding, increasing its free concentration and thus increasing gene transcription. Occasional anecdotal reports from humans intoxicated with vitamin D appear to support the latter mechanism. Although current data support the viewpoint that the biomarker plasma 25(OH)D concentration must rise above 750 nmol/L to produce vitamin D toxicity, the more prudent upper limit of 250 nmol/L might be retained to ensure a wide safety margin. Am J Clin Nutr 2008;88(suppl):582S–6S.

INTRODUCTION

Research has shown that the mechanism of action of vitamin D\textsubscript{3}, through its hormonal form, 1α,25-dihydroxyvitamin D\textsubscript{3} \([1\alpha,25(\text{OH})\textsubscript{2}D\textsubscript{3}]\), involves a nuclear receptor [vitamin D receptor (VDR)] that regulates the transcription of several target genes in a variety of vitamin D target cells that are primarily involved in calcium homeostasis and cell differentiation (1). To allow vitamin D to achieve these important regulatory functions, normal physiology has evolved several specific proteins that constitute the vitamin D signal transduction system (Figure 1).

These specialized proteins, in addition to the VDR and its associated transcriptional coactivators, include the plasma transport protein, vitamin D binding protein (DBP); the activating cytochrome P450s (CYP2R1, CYP27A1, and CYP27B1); and the catabolic cytochrome P450 CYP24A1. CYP24A1 plays a critical role in the degradation of both 25-hydroxyvitamin D\textsubscript{3} \([25(\text{OH})D\textsubscript{3}]\) and 1α,25(OH)\textsubscript{2}D\textsubscript{3} through a side-chain hydroxylation and cleavage pathway known as C-24 oxidation (5). Recent research using the CYP24A1-null mouse has shown that CYP24A1 plays a vital role in vivo in that its absence leads to an inability to degrade vitamin D metabolites to C-24 oxidation products or 26,23-lactone products. This resulted in hypercalcemia, nephrocalcinosis, and death in 50% of animals (6).

Because vitamin D toxicity resulting from excessive vitamin D intakes (hypervitaminosis D) is also accompanied by hypercalcemia, toxicity is remarkably similar to the CYP24A1-null mouse. One can therefore postulate that overactivity of the vitamin D signal transduction system in hypervitaminosis D is also the result of an inability of the catabolic system involving CYP24A1 to keep up with the target cell levels of activated vitamin D metabolites. Indeed, investigators have postulated several variations of this theme, each involving a different metabolite (or metabolites) that, together, overwhelm the vitamin D signal transduction process, to explain the vitamin D toxicity of hypervitaminosis D. I review these explanations of vitamin D toxicity, along with the animal and human data assembled to support them.

IMPORTANT DETERMINANTS OF VITAMIN D PHARMACOKINETICS RELEVANT TO HYPERVITAMINOSIS D

Vitamin D\textsubscript{3} is a lipophilic molecule similar to its closely related lipid precursor cholesterol, so it requires a protein carrier for solubility in plasma. Its mono-, di-, and tri-hydroxylated metabolites show progressively increasing polarity, culminating in the water-soluble biliary form calcitroic acid (7). When absorbed from the gut, vitamin D enters the circulation on chylomicrons first, and it is only slowly transferred to DBP (8). Vitamin D\textsubscript{3} has relatively low affinity for DBP; reviews estimate this at between 1 \(\times\) 10\textsuperscript{-7} and 1 \(\times\) 10\textsuperscript{-8} mol/L (9, 10).

Transport of dietary vitamin D contrasts significantly with that of vitamin D\textsubscript{3} made during skin synthesis, which is mainly bound to calcium carbonate in the epidermal cells (11). In the skin, vitamin D is produced from 7-diol vitamin D\textsubscript{3} \([7(\text{OH})D\textsubscript{3}]\) through a side-chain hydroxylation and cleavage pathway known as C-24 oxidation (12). Recently, it has been hypothesized that, under some conditions, increased skin production of vitamin D\textsubscript{3} might cause hypercalcemia (13, 14). Recent evidence suggests that vitamin D\textsubscript{3} is also produced from vitamin D\textsubscript{2} (15). Vitamin D\textsubscript{2} has a high affinity for DBP and is more readily hydroxylated than vitamin D\textsubscript{3} (16). Thus, it is possible that increased skin production of vitamin D\textsubscript{3} could cause vitamin D toxicity by competing with vitamin D\textsubscript{2} and, by this mechanism, displace vitamin D\textsubscript{2} from DBP (17, 18). This could lead to vitamin D\textsubscript{2} deficiency, which is supported by reports from humans who have ingested high doses of vitamin D\textsubscript{2} (19). Other evidence suggests that vitamin D\textsubscript{3} might cause hypercalcemia by stimulating calcium uptake from bone (20). To explain this paradox, it has been suggested that vitamin D\textsubscript{3} might cause hypercalcemia by reducing bone resorption and increasing bone formation (21, 22). However, this explanation is unlikely, because vitamin D\textsubscript{3} is not produced in vivo from vitamin D\textsubscript{2} (23). Therefore, the mechanism by which vitamin D\textsubscript{3} causes hypercalcemia is unknown, and further research is needed to elucidate this mechanism.

1 From the Departments of Biochemistry and Medicine, Queen’s University, Kingston, Ontario, Canada.
3 Supported by grants from the Canadian Institutes for Health Research and Cytochrome Inc, Markham, Ontario, Canada.
4 Address reprint requests to G Jones, Department of Biochemistry, Queen’s University, Kingston, Ontario K7L 3N6, Canada. E-mail: gj1@queensu.ca.

582S

to DBP (8). The consequence of chylomicron transport of dietary vitamin D is the possibility of uptake by peripheral tissues, such as adipose tissue and muscle, due to the action of lipoprotein lipase (11). The liver takes up the vitamin D left in the chylomicron remnant and quickly removes it from the bloodstream.

The loss into tissue and liver pools thus logically explains the short plasma half-life, ≈4–6 h, of physiologically relevant doses of vitamin D (11). Similar studies with radiolabeled vitamin D have shown that the whole-body half-life is ≈2 mo (11).

The liver converts vitamin D into 25(OH)D, a process that some attribute to a microsomal cytochrome P450 enzyme, CYP2R1, or the mitochondrial cytochrome P450 CYP27A1; neither is subject to tight regulation (12). 25(OH)D quickly enters the plasma pool that constitutes the predominant pool of vitamin D in the body, with a capacity of ≈4.5 μmol/L. 25(OH)D₃ and 25(OH)D₂, its vitamin D₂ counterpart, have a strong affinity for DBP at 5 × 10⁻⁸ mol/L, which is at least an order of magnitude higher than that of its vitamin D precursors (9, 10). As a consequence, 25(OH)D₃ has a half-life of 15 d in the circulation. The normal circulating level of 25(OH)D [25(OH)D₃ + 25(OH)D₂] in the blood is only 25–200 nmol/L (13), indicating that ligand only occupies 2–5% of DBP in the physiologic state.

The dihydroxy- metabolites have widely differing affinities for DBP, with 25(OH)D₂-26,23-lactone binding 3–5 times as tightly as 25(OH)D₃. The inactive metabolites 24,25(OH)₂D₃ and 25,26(OH)₂D₃ bind with equal affinity as 25(OH)D₃, and the active form 1α,25(OH)₂D₃ binds DBP with an affinity of 2 × 10⁻⁷ mol/L, an order of magnitude less than its precursor (12, 13). 1α,25(OH)₂D₃ has a half-life of 10–20 h (14, 15), although this depends to some extent on the state of the highly inducible catabolic machinery. The accumulation of these metabolites in the bloodstream is mainly a function of their affinity for DBP, although rate of synthesis and degradation must also play a partial role.

Recent studies (16) have conclusively shown that CYP24A1 is responsible for the formation of several principal accumulating metabolites, 24,25(OH)₂D₃ and 25(OH)D₃-26,23-lactone, as well as the catabolite calcitroic acid. Research has not identified the origin of the minor metabolite 25,26(OH)₂D₃, although studies have shown that several CYPs, such as CYP27A1 and CYP24, hydroxylate at C26 (1, 12) under in vitro conditions. Of course, although research has proven that renal CYP27B1 synthesizes the circulating pool of 1α,25(OH)₂D₃, the amount of vitamin D channeled into this active form is tightly regulated (17) and studies have estimated that it is only a small percentage of the total body pool of vitamin D.

Measurements of the plasma level show that circulating 1α,25(OH)₂D₃ is in the picomolar range, a concentration 1000 times lower than that of 25(OH)D. Molecular probes for CYP27B1 mRNA based on reverse transcriptase–polymerase
chain reaction and for CYP27B1 protein based on immune localization studies have shown that this “activating” CYP is expressed not only in the kidney but also in several extrarenal tissues; in addition, it is subject to different regulation than the renal enzyme (Figure 1; 2, 3). This extrarenal 1α-hydroxylase appears to have a paracrine or autocrine function to augment local production of 1α,25(OH)2D3 in selected vitamin D target cells (2, 3), although this remains largely unproven.

Accordingly, vitamin D’s lipophilicity, affinity of its metabolites for plasma transport carriers, and rates of synthesis and degradation of its metabolites by the vitamin D–related CYPs largely determine the pharmacokinetics and distribution of vitamin D in the body. The affinity of 1α,25(OH)2D3 for the VDR plays a major role in determining its role as the sole active metabolite under physiologic conditions; the other components of the vitamin D signal transduction machinery are equally important in keeping the inactive metabolites in the plasma pool and away from the nuclear transcriptional machinery. However, in vitamin D toxicity associated with hypervitaminosis D, this is almost certainly not the case; vitamin D metabolites other than 1α,25(OH)2D3 could interfere with the normal delivery of 1α,25(OH)2D3 to the target cell or else have effects themselves.

**EVIDENCE FROM STUDIES OF VITAMIN D INTOXICATION IN ANIMALS**

Researchers have conducted several animal studies involving systematic vitamin D intoxication over the past 3 decades in a variety of different species, including rats, cows, pigs, rabbits, dogs, and horses (18–23). As knowledge of vitamin D metabolism might lead one to expect, vitamin intoxication results in elevation of the plasma concentrations of vitamin D3, 25(OH)D3; 24,25(OH)2D3; 25,26(OH)2D3; 25,26(OH)2D3; and 25(OH)D3-26,23-lactone, although it rarely raises plasma 1α,25(OH)2D3. The studies by Littledike and Horst (19, 20) in pigs and dairy cows are quite definitive on this point and suggest that the renal CYP27B1 is effectively turned off.

Focus has therefore shifted to the levels of other vitamin D metabolites correlated with toxicity, especially the plasma threshold of 25(OH)D that must be exceeded to cause hypercalcemia. One of the most widely cited publications in this area is the work of Shephard and DeLuca (18), who acutely intoxicated rats with graded oral doses of vitamin D3 (0.65 to 6500 ng/d for 14 d) or 25(OH)D3 (0.46 to 4600 ng/d for 14 d). They measured all major vitamin D metabolites by reliable HPLC and competitive binding assays at the end of the dosing period. Vitamin D3 and 25(OH)D3 concentrations rose to micromolar levels in plasma of rats given the highest intakes of vitamin D3, resulting in marked hypercalcemia. All dihydroxylated metabolites, including 24,25(OH)2D3; 25,26(OH)2D3; and 25(OH)D3-26,23-lactone, also rose to concentrations higher than 100 nmol/L, but the level of plasma 1α,25(OH)2D3 remained within the normal range.

The study design did not allow for repeated measurements of plasma vitamin D metabolite levels as the hypercalcemia developed in the animals, leaving open the possibility that plasma 1α,25(OH)2D3 initially rose and was subsequently suppressed in response to hypercalcemia. Nevertheless, other animal studies of hypervitaminosis D (19, 20) have also repeatedly failed to demonstrate a significant elevation of the hormonal form.

The 10-fold increments in the dose of vitamin D3 used in the study by Shephard and DeLuca (18) did not allow for a very precise prediction of the 25(OH)D3 threshold that can be correlated with hypercalcemia (toxicity), because a vitamin D3 dose of 65 ng/d resulted in a 25(OH)D3 concentration of 74 ± 15 ng/mL (185 ± 36 nmol/L) and no hypercalcemia, whereas a vitamin D3 dose of 650 ng/d resulted in a 25(OH)D3 concentration of 643 ± 93 ng/mL (1608 ± 232 nmol/L) and profound hypercalcemia (total calcium was 12.4 mg/dL). However, the studies with 25(OH)D3 revealed a remarkable finding: a dose of 460 ng/d resulted in 25(OH)D3 concentrations of 436 ± 53 ng/mL (1090 ± 132 nmol/L) with normocalcemia.

Although this study suggests that rodents can tolerate plasma 25(OH)D3 concentrations in the range of 250–1000 nmol/L, such tolerance represents a relatively unique situation for 25(OH)D3 administration, in which high circulating vitamin D3 that is present when vitamin D3 is the dietary form does not accompany elevated concentrations of 25(OH)D3. Based on a variety of studies in several animal species, it appears that the plasma 25(OH)D3 concentrations associated with toxicity are always in excess of 375 nmol/L. Furthermore, small differences between various mammalian species used in animal experiments are largely irrelevant to the toxicity issue and render the animal data valuable to our discussion.

**ANECDOTAL EVIDENCE FROM STUDIES OF VITAMIN D INTOXICATION IN HUMANS**

For ethical reasons, no systematic studies have examined vitamin intoxication in humans. But numerous anecdotal reports over the years have described accidental vitamin D intoxication with either vitamin D3 or vitamin D2 (17, 24–33; many reviewed in 34). Because most of these studies measured 25(OH)D [and sometimes 1α,25(OH)2D], it is worth reviewing the vitamin D metabolite values reported with overt toxicity symptoms.

Although an occasional report did find evidence of modest elevations of 1α,25(OH)2D (17), all reported that 25(OH)D concentrations were well above the normal range at 710–1587 nmol/L, with several patients exhibiting values consistently around 750 nmol/L. In addition, several reports have documented clusters of patients with vitamin D–contaminated food sources (35, 36). In a study of 35 hypervitaminotic patients with hypercalcemia resulting from chronic ingestion of overfortified milk (35), the average 25(OH)D concentration was 560 nmol/L (range: 140–1490 nmol/L). In an extended family group accidentally intoxicated with a vitamin D concentrate (peanut oil solution containing 2 × 106 IU cholecalciferol), Pettifor et al (36) showed that 25(OH)D concentrations ranged from 847 to 1652 nmol/L in intoxicated family members, whereas plasma 1α,25(OH)2D concentrations were within the normal range in 8 of 11 patients. A perusal of these data and the anecdotal reports leads this reviewer to the same conclusion as that of Vieth (34); namely, that hypercalcemia only results when 25(OH)D3 concentrations have persistently been above 375–500 nmol/L.

**THEORIES ABOUT THE MECHANISM OF VITAMIN D TOXICITY**

Researchers have proposed 3 major theories about the mechanism of vitamin D toxicity. All involve increased concentrations of a vitamin D metabolite reaching the VDR in the nucleus of target cells and causing exaggerated gene expression. At issue
is the offending vitamin D metabolite and how it becomes elevated. The 3 hypotheses to explain this are as follows:

1) Vitamin D intake raises plasma 1α,25(OH)2D concentrations, which increase cellular 1α,25(OH)2D concentrations.

2) Vitamin D intake raises plasma 25(OH)D to μmol/L concentrations that exceed the DBP binding capacity and “free 25(OH)D” enters the cell, where it has direct effects on gene expression.

3) Vitamin D intake raises the concentrations of many vitamin D metabolites, especially vitamin D itself and 25(OH)D. These concentrations exceed the DBP binding capacity and cause release of “free” 1α,25(OH)2D, which enters target cells.

In weighing each of these hypotheses, it is useful to consider other factors, in addition to elevated dietary vitamin D intakes, that result in symptoms of vitamin D toxicity. One disease that can result in vitamin D toxicity is the granulomatous condition sarcoidosis, but only when strong evidence exists that the mechanism involves consistently elevated plasma 1α,25(OH)2D concentrations due to overexpression of unregulated extrarenal CYP27B1 in the face of normal concentrations of 25(OH)D (37–39). In addition, the widespread use of calcitriol or its analogues to treat secondary hyperparathyroidism in chronic kidney disease occasionally results in such symptoms as hypercalcemia, osteodystrophy, and CYP24) allows us to theorize in broad terms about how vitamin D toxicity might arise from hypervitaminosis D. Of the 3 hypotheses put forward to explain the triggering event for toxicity, increases in total 25(OH)D and free 1α,25(OH)2D concentrations are the most plausible, although they remain unproven. However, even in the absence of definitive evidence to establish the responsible metabolite, the wealth of animal studies and human anecdotal reports of vitamin D intoxication indicate that plasma 25(OH)D is a good biomarker for toxicity, and the threshold for toxic symptoms is ≈750 nmol/L. This threshold value implies that 25(OH)D concentrations up to the currently considered upper limit of the normal range, namely 250 nmol/L, are safe and still leave a broad margin for error because values significantly higher than this value have never been associated with toxicity.

In fact, Bikle et al (43, 44) have pioneered methods for determining free concentrations of 1α,25(OH)2D3 and 25(OH)D, in clinical samples that are based on measuring DBP and total metabolites. Accordingly, in hypervitaminosis D, in which vitamin D metabolites [such as vitamin D3; 25(OH)D3; 24,25(OH)2D3; 25,26(OH)2D3; and 25(OH)D1,26,23-lactone] saturate the DBP in the bloodstream, the free concentrations of some of the most important metabolites, such as 1α,25(OH)2D3 and 25(OH)D3, could increase significantly.

In the investigation of the family accidentally intoxicated by vitamin D3 in peanut oil discussed above (36), the authors used the methods of Bikle (43, 44) to investigate free 1α,25(OH)2D3 concentrations. They found that unlike total 1α,25(OH)2D3 concentrations, which remained within the normal range in 8 of 11 family members, free 1α,25(OH)2D3 concentrations were ≥2 SDs above the reference range in 6 of 9 patients studied. The authors concluded that the micromolar concentrations of 25(OH)D and other metabolites displace free 1α,25(OH)2D3 from DBP.

These investigators also simulated in vitro the displacement of 1α,25(OH)2D3 from DBP noted in hypervitaminotic plasma by adding 25(OH)D3 to normal serum at the 800-nmol/L concentration found in hypervitaminotic plasma. They found a virtual doubling of free 1α,25(OH)2D3 concentrations. Although these results are quite convincing, few other data are available to support hypothesis 3, and one must conclude that the theory remains unproven.

CONCLUSIONS

Our current understanding of the components of the vitamin D signal transduction machinery (DBP, activating CYPs, VDR, and CYP24) allows us to theorize in broad terms about how vitamin D toxicity might arise from hypervitaminosis D. Of the 3 hypotheses put forward to explain the triggering event for toxicity, increases in total 25(OH)D and free 1α,25(OH)2D concentrations are the most plausible, although they remain unproven. However, even in the absence of definitive evidence to establish the responsible metabolite, the wealth of animal studies and human anecdotal reports of vitamin D intoxication indicate that plasma 25(OH)D is a good biomarker for toxicity, and the threshold for toxic symptoms is ≈750 nmol/L. This threshold value implies that 25(OH)D concentrations up to the currently considered upper limit of the normal range, namely 250 nmol/L, are safe and still leave a broad margin for error because values significantly higher than this value have never been associated with toxicity.

David Prosser helped with the artwork used in this review. The author had no conflicts of interest.

REFERENCES


